Colorectal cancer is the fourth most commonly diagnosed type of cancer in the United States. Though various treatments are available for it, certain tumour cells are therapy-resistant. Now, research suggests that an antifungal drug may be effective against these persistent cells. The drug itraconazole is typically used in the treatment of fungal infections. These can include certain types of vaginal yeast (vulvovaginal candidiasis) and fungal infections on the hands and feet (Tinea pedis and Tinea manuum). But researchers from the Cancer Research UK Cambridge Institute have suggested a brand-new use for this substance namely, as a treatment that is able to eliminate dormant tumour cells in colorectal cancer. This is one of the most common cancer types in the U.S., and an estimated 140,250 people will learn that they have this disease in 2018, according to the National Cancer Institute (NCI). “One of the biggest challenges in treating any cancer is the diversity of different cells within the same tumour,” explains co-lead author Dr. Simon Buczacki, who participated in the new study investigating the effect of itraconazole on dormant colorectal cancer cells. In this study, he continues, the team “targeted a type of cell that lies asleep within bowel tumours, remaining unresponsive to treatment and putting the patient at risk of their cancer coming back.” In experiments conducted on mice, Dr. Buczacki and team found that the antifungal drug may be able to trigger the death of a type of colorectal cancer cell typically immune to treatment. These tumour cells are found in a state of inactivity, or “dormancy,” so they do not respond to the usual therapies, such as chemotherapy, that target and destroy active cancer cells. So, even as a treatment is effective in destroying most malignant cells, these dormant units will remain unaffected, putting the person at risk of having a recurrence of the cancer later on. In the study the findings of which have been published in the Journal of Experimental Medicine the researchers worked with cancer tumours grown in mice models of colorectal cancer. First of all, they focused on identifying which signalling pathways were involved in controlling cell dormancy in the case of cancer tumours. They saw that, for colorectal cancer, there are two: Wnt and “hedgehog” pathways. Then, they tested the effectiveness of various drugs on these two pathways, and it was then that they noticed itraconazole’s therapeutic potential. Dr. Buczacki and team discovered that itraconazole interfered with the Wnt pathway, which led to the elimination of the dormant cells and blocked the growth of the cancer tumour. “What’s interesting is that this drug seems to kick both dormant and non-dormant cells into action,” notes Dr. Buczacki. “It forces cells back into a short cycle of growth,” he explains, “before slamming on an irreversible ‘stop’ button, entering a permanent standstill that’s known as senescence.” Following these promising results, the team would eventually like to test the effectiveness of this drug in clinical trials, on patients with colorectal cancer at an advanced stage. Another step would be to ascertain whether itraconazole would be more effective on its own, or used in combination therapy, administered alongside other drugs. Prof. Greg Hannon the director of the Cancer Research UK Cambridge Institute comments on the discovery, calling the research an “innovative study” that “has taken a step toward addressing one of the biggest challenges in cancer research.” “The presence of drug-resistant, dormant tumour cells is a problem in many types of cancer,” he says.
Medical News Today, 3 June 2018 ;